1-(3,4-Dihydroxyphenyl)-2-[(4-hydroxy-5,6-dimethylthieno[2,3-d]pyrimidin-2-yl)sulfanyl]ethanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(3,4-Dihydroxyphenyl)-2-[(4-hydroxy-5,6-dimethylthieno[2,3-d]pyrimidin-2-yl)sulfanyl]ethanone
• 英文别名: 2-[2-(3,4-dihydroxyphenyl)-2-oxoethyl]sulfanyl-5,6-dimethyl-3H-thieno[2,3-d]pyrimidin-4-one
• 化学式: C₁₆H₁₄N₂O₄S₂
• 分子量: 362.4
• InChiKey: FBFZQTVPMLIDPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  153
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Flavivirus protease inhibitors
  申请人：GEORGETOWN UNIVERSITY

  公开号：US10471082B2

  公开（公告）日：2019-11-12

  Methods of treating or preventing a Flavivirus infection in a subject are provided. The methods comprise administering to the subject a therapeutically effective amount of a Flavivirus inhibitor, e.g., a Flavivirus protease inhibitor. These methods are useful in treating and/or preventing Flavivirus infections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus. Methods of inhibiting a Flavivirus protease in a cell are also provided.

  提供了治疗或预防受试者感染弗拉维病毒的方法。这些方法包括向受试者施用治疗有效量的弗拉维病毒抑制剂，例如弗拉维病毒蛋白酶抑制剂。这些方法可用于治疗和/或预防弗拉维病毒感染，例如西尼罗河病毒、登革病毒和日本脑炎病毒。还提供了抑制细胞中黄病毒蛋白酶的方法。
• FLAVIVIRUS PROTEASE INHIBITORS
  申请人：GEORGETOWN UNIVERSITY

  公开号：US20150272976A1

  公开（公告）日：2015-10-01

  Methods of treating or preventing a Flavivirus infection in a subject are provided. The methods comprise administering to the subject a therapeutically effective amount of a Flavivirus inhibitor, e.g., a Flavivirus protease inhibitor. These methods are useful in treating and/or preventing Flavivirus infections such as, for example, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus. Methods of inhibiting a Flavivirus protease in a cell are also provided.
• USE OF SMALL MOLECULE INHIBITORS TO KLF10 FOR MODULATION OF T REGULATORY CELLS AND CANCER IMMUNOTHERAPY
  申请人：THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US20170121318A1

  公开（公告）日：2017-05-04

  The invention relates to compositions and methods for inhibiting Krüppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.